# NRM-823

Source: https://onco.cc/drugs/nrm-823/  
OnCo record `nrm-823` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NRM-823 is an experimental T cell engager from Normunity, in phase 1 trials for head and neck squamous cell carcinoma, oesophageal squamous cell carcinoma and oesophageal adenocarcinoma and other cancers.

## Summary

NRM-823 is a T cell engager (bispecific) from Normunity. A first-in-class T cell engager that binds a novel tumour-specific target which the company says is expressed on multiple types of solid tumours and absent in normal systemic tissues. The company has not named the target. Its furthest stage is phase 1, for head and neck squamous cell carcinoma, oesophageal squamous cell carcinoma, oesophageal adenocarcinoma and gastric adenocarcinoma. ClinicalTrials.gov registers it in one study linked below. First patient dosed in the phase 1a/1b study, announced 5 November 2025; registry status RECRUITING. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: NRM-823
- Modality: T cell engager (bispecific)
- Mechanism: A first-in-class T cell engager that binds a novel tumour-specific target which the company says is expressed on multiple types of solid tumours and absent in normal systemic tissues. The company has not named the target.

## Sources

- Normunity: normunity.com: https://normunity.com/pipeline/
- Normunity: normunity.com: https://normunity.com/normunity-announces-first-patient-dosed-in-phase-1-clinical-study-of-nrm-823-a-t-cell-engager-against-a-novel-tumor-specific-target-in-patients-with-solid-tumors/
- Normunity: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07182149
- ClinicalTrials.gov: trials of NRM-823: https://clinicaltrials.gov/search?intr=NRM-823

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Oesophageal and junctional adenocarcinoma](https://onco.cc/cancers/oesophageal-adenocarcinoma/), [Oesophageal squamous cell carcinoma](https://onco.cc/cancers/oesophageal-squamous-cell-carcinoma/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- companies: [Normunity](https://onco.cc/companies/normunity/)
- trials: [A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors](https://onco.cc/trials/nct07182149/)

---
JSON: https://onco.cc/api/v1/entities/nrm-823.json